The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia

  1. Prades, R.
  2. Munarriz-Cuezva, E.
  3. Urigüen, L.
  4. Gil-Pisa, I.
  5. Gómez, L.
  6. Mendieta, L.
  7. Royo, S.
  8. Giralt, E.
  9. Tarragó, T.
  10. Meana, J.J.
Journal:
European Neuropsychopharmacology

ISSN: 1873-7862,  0924-977X

Year of publication: 2017

Volume: 27

Issue: 2

Pages: 180-191

Type: Article

DOI: 10.1016/J.EURONEURO.2016.11.016 GOOGLE SCHOLAR

Sustainable development goals

Data source: Scopus